Filter News
Area of Research
- (-) Neutron Science (4)
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (3)
- Biology and Environment (3)
- Building Technologies (1)
- Clean Energy (30)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (1)
- Isotopes (1)
- Materials (6)
- Materials for Computing (2)
- National Security (1)
- Supercomputing (1)
- Transportation Systems (1)
News Topics
- (-) Advanced Reactors (1)
- (-) Biomedical (3)
- (-) Physics (2)
- 3-D Printing/Advanced Manufacturing (1)
- Bioenergy (1)
- Biology (1)
- Composites (1)
- Computer Science (2)
- Coronavirus (1)
- Fusion (1)
- Isotopes (1)
- Materials (2)
- Materials Science (3)
- Molten Salt (2)
- Nanotechnology (2)
- Neutron Science (13)
- Nuclear Energy (3)
- Quantum Science (1)
- Space Exploration (1)
Media Contacts
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
The COHERENT particle physics experiment at the Department of Energy’s Oak Ridge National Laboratory has firmly established the existence of a new kind of neutrino interaction.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
A team of scientists has for the first time measured the elusive weak interaction between protons and neutrons in the nucleus of an atom. They had chosen the simplest nucleus consisting of one neutron and one proton for the study.
A team of scientists, led by University of Guelph professor John Dutcher, are using neutrons at ORNL’s Spallation Neutron Source to unlock the secrets of natural nanoparticles that could be used to improve medicines.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.